NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Search Results for Viread


Filter Articles: Clinical News | Consumer News | Business News | All News | More Options

Results 1 - 20      Next >


Refine Search
Display Mode: Context | Summary
Gilead Announces Data Demonstrating Pharmacokinetic Boosting Activity of GS 9350
2009 FEB 23 ... in humans. Important Information About Truvada Truvada, a combination of Emtriva® and Viread®, is indicated in combination with other antiretroviral agents (such as non-nucleoside ...
Subject: Gilead Sciences, Inc.
Price: $3.00
*
Gilead Announces Long-Term Data from Two Pivotal Phase III Studies Evaluating Viread(R) for Chronic Hepatitis B
2009 NOV 16 ... clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B ...
Subject: Gilead Sciences, Inc.
Price: $3.00
*
Gilead Sciences Announces Record Second Quarter 2009 Financial Results
2009 AUG 3 ... States and Europe. Other Antiviral Products Other antiviral product sales, including Viread® (tenofovir disoproxil fumarate), Hepsera® (adefovir dipivoxil) and ...
Subject: Gilead Sciences, Inc.
Price: $3.00
*
Gilead Sciences Announces Record Third Quarter 2009 Financial Results
2009 NOV 2 ... of 2008, driven primarily by sales volume growth in the United States and Europe. Viread Viread® (tenofovir disoproxil fumarate) sales increased nine percent to $169.7 ...
Subject: Gilead Sciences, Inc.
Price: $3.00
*
Landmark Five-Year African Study Indicates That HIV Therapy May Be Given Safely in Resource-Limited Settings Without Routine Laboratory Monitoring
2009 AUG 3 ... toxicity. In this study, 74 percent of patients were on a treatment regimen containing Viread® (tenofovir disoproxil fumarate). At baseline, more than 50 percent of patients had ...
Subject: Gilead Sciences, Inc.
Price: $3.00
*
NCCN Updates Infection Guidelines to Include Information About H1N1 Virus (Swine Flu)
2009 AUG 17 ... Inc.) to the Antibacterial Agents Tables and tenofovir disoproxil fumarate (Viread®, Gilead Sciences, Inc.) to the Antiviral Agents Tables. NCCN Clinical ...
Subject: Cancer
Price: $3.00
*
New patents research from T. Amin and colleagues discussed
2009 OCT 5 ... case-study examples, including the antiretroviral tenofovir disoproxil fumarate (TDF, or Viread), we demonstrate the importance of having outside experts participate in the review of ...
Subject: Patents
Price: $3.00
*
Studies from Imperial College provide new data on HIV/AIDS prevention
2009 AUG 3 ... reported in journals and at conferences, using the search terms Tenofovir/gs4331/viread, pregnant/pregnancy, lactate, lactation, natal, reproduce/reproduction, ...
Subject: HIV/AIDS Prevention
Price: $3.00
*
Gilead Announces Two-Year Data from Pivotal Phase III Studies Evaluating Viread for Chronic Hepatitis B
2008 NOV 17 ... clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread(R) (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus ...
Subject: Gilead Sciences, Inc.
Price: $3.00
*
Gilead Sciences and Merck & Co., Inc. Enter Into an Agreement to Register and Distribute HIV Medication Atripla Efavirenz 600 mg/ Emtricitabine 200 mg/ Tenofovir Disoproxil Fumarate 300 mg in Twelve Countries
2008 AUG 18 ... fumarate are commercialized by Gilead Sciences under the tradenames Emtriva(R) and Viread(R), respectively, and together as the fixed-dose combination Truvada(R). ...
Subject: Gilead Sciences, Inc.
Price: $3.00
*
Gilead Sciences Announces Second Quarter 2008 Financial Results
2008 AUG 4 ... States, as well as the recent launches in certain European countries. -- Viread Viread(R) (tenofovir disoproxil ...
Subject: Gilead Sciences, Inc.
Price: $3.00
*
Gilead Sciences Announces Third Quarter 2008 Financial Results
2008 NOV 3 ... the United States, as well as launches in certain European countries. -- Viread Viread(R) (tenofovir disoproxil ...
Subject: Gilead Sciences, Inc.
Price: $3.00
*
HIV prevention researchers to compare common ARV as a pill and vaginal gel in unique study
2008 JUL 21 ... In its tablet form, tenofovir disoproxil fumarate, known by the brand name Viread, is a mainstay of one of the most widely used regimens for treating HIV. The active ...
Subject: Microbicide Trials Network
Price: $3.00
*
ISENTRESS raltegravir, Merck's First in Class Integrase Inhibitor, Reduced HIV Viral Load and Increased CD4 Cell Counts Through 96 Weeks in Treatment-Naive HIV-Infected Patients When Taken With Other Anti
2008 AUG 18 ... received either ISENTRESS administered orally twice daily in combination with tenofovir (Viread® ) and lamivudine (Epivir®) or 600 mg efavirenz dosed orally once daily in combination ...
Subject: Merck & Co., Inc.
Price: $3.00
*
Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
2008 JUL 21 ... Inc. (NASDAQ:GILD), has initiated the first head-to-head study of clevudine and Viread(R) (tenofovir disoproxil fumarate) administered separately, versus their combination, ...
Subject: HIV/AIDS
Price: $3.00
*

Results 1 - 20      Next >




-----------------------
PR Login